EU's CHMP green lights three immune-oncology drugs
This article was originally published in Scrip
Executive Summary
The EMA's scientific committee, the CHMP, has given its nod of approval for Bristol-Myers Squibb's Opdivo (nivolumab) for use in European patients with squamous non-small cell lung cancer, alongside positive recommendations for two other new immune-oncology products: Merck & Co's Keytruda (pembrolizumab) and United Therapeutics' Unituxin (dinutuximab).